scholarly journals Impact of Use Frequency of a Mobile Diabetes Management App on Blood Glucose Control: Evaluation Study (Preprint)

2018 ◽  
Author(s):  
Josep Vehi ◽  
Jordi Regincós Isern ◽  
Adrià Parcerisas ◽  
Remei Calm ◽  
Ivan Contreras
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Diabetes Management ◽  
Blood Glucose Control ◽  
Evaluation Study ◽  
High Blood Glucose ◽  
Group A ◽  
Control Evaluation ◽  
Group B ◽  
The Impact

BACKGROUND Technology has long been used to carry out self-management as well as to improve adherence to treatment in people with diabetes. However, most technology-based apps do not meet the basic requirements for engaging patients. OBJECTIVE This study aimed to evaluate the effect of use frequency of a diabetes management app on glycemic control. METHODS Overall, 2 analyses were performed. The first consisted of an examination of the reduction of blood glucose (BG) mean, using a randomly selected group of 211 users of the SocialDiabetes app (SDA). BG levels at baseline, month 3, and month 6 were calculated using the intercept of a regression model based on data from months 1, 4, and 7, respectively. In the second analysis, the impact of low and high BG risk was examined. A total of 2692 users logging SDA ≥5 days/month for ≥6 months were analyzed. The highest quartile regarding low blood glucose index (LBGI) and high blood glucose index (HBGI) at baseline (t1) was selected (n=74 for group A; n=440 for group B). Changes in HBGI and LBGI at month 6 (t2) were analyzed. RESULTS For analysis 1, baseline BG results for type 1 diabetes mellitus (T1DM) groups A and B were 213.61 (SD 31.57) mg/dL and 206.43 (SD 18.65) mg/dL, respectively, which decreased at month 6 to 175.15 (SD 37.88) mg/dL and 180.6 (SD 40.47) mg/dL, respectively. For type 2 diabetes mellitus (T2DM), baseline BG was 218.77 (SD 40.18) mg/dL and 232.55 (SD 46.78) mg/dL, respectively, which decreased at month 6 to 160.51 (SD 39.32) mg/dL and 173.14 (SD 52.81) mg/dL for groups A and B, respectively. This represents a reduction of estimated A1c (eA1c) of approximately 1.3% (P<.001) and 0.9% (P=.001) for T1DM groups A and B, respectively, and 2% (P<.001) for both A and B T2DM groups, respectively. For analysis 2, T1DM baseline LBGI values for groups A and B were 5.2 (SD 3.9) and 4.4 (SD 2.3), respectively, which decreased at t2 to 3.4 (SD 3.3) and 3.4 (SD 1.9), respectively; this was a reduction of 34.6% (P=.005) and 22.7% (P=.02), respectively. Baseline HBGI values for groups A and B were 12.6 (SD 4.3) and 10.6 (SD 4.03), respectively, which decreased at t2 to 9.0 (SD 6.5) and 8.6 (SD 4.7), respectively; this was a reduction of 30% (P=.001) and 22% (P=.003), respectively. CONCLUSIONS A significant reduction in BG was found in all groups, independent of the use frequency of the app. Better outcomes were found for T2DM patients. A significant reduction in LBGI and HBGI was found in all groups, regardless of the use frequency of the app. LBGI and HBGI indices of both groups tend to have similar values after 6 months of app use.

scholarly journals Impact of Use Frequency of a Mobile Diabetes Management App on Blood Glucose Control: Evaluation Study

10.2196/11933 ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. e11933 ◽  
Author(s):  
Josep Vehi ◽  
Jordi Regincós Isern ◽  
Adrià Parcerisas ◽  
Remei Calm ◽  
Ivan Contreras
Keyword(s):  
Blood Glucose ◽  
Glucose Control ◽  
Diabetes Management ◽  
Blood Glucose Control ◽  
Evaluation Study ◽  
Control Evaluation

Pharmacist Impact on Physician Practices Related to Diabetes Management

2021 ◽  
Vol 8 (4) ◽  
pp. 560-575
Author(s):  
Amina Ammar ◽  
Lindsay M. Darghali ◽  
Wassim Tarraf ◽  
Helen D. Berlie ◽  
Linda A. Jaber
Keyword(s):  
Blood Pressure ◽  
Diabetes Management ◽  
Individual Treatment ◽  
Diabetic Patients ◽  
Composite Target ◽  
Physician Practices ◽  
Physical Presence ◽  
Group A ◽  
Group B ◽  
The Impact

To examine the impact of a pharmacist’s physical presence on (1) the achievement of individual and combined targets for hemoglobin A1c (A1C), blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) (composite target), and (2) physician practices in relation to the American Diabetes Association (ADA) standards of medical care.   Methods A retrospective, comparative study of randomly selected diabetic patients seen within an underserved primary care setting at least twice annually between June 1, 2018- December 31, 2019. Patients were allocated by whether they had received care in one of the physician-pharmacist clinics (Group A) or the physician-only clinic (Group B). Study outcomes included the proportion of patients achieving the composite and individual treatment targets for A1C, BP, and LDL-C.   Results A total of 394 patients were included; Majority were underserved African Americans. The composite target was attained by 20% of participants in Group A and 13% in Group B (p=0.09). There were no statistically significant differences in achievement of individual targets between groups. A significantly higher proportion of participants in Group A achieved better control of diastolic blood pressure control (85% vs. 74%), had microalbuminuria tested (50% vs. 12%), were prescribed aspirin (43% vs. 32%), and had lower utilization of non-insulin glucose-lowering agents relative to those in Group B.   Conclusion The impact of a pharmacist’s physical presence on physician practice demonstrated a general trend towards improvement in clinical outcomes related to diabetes management. Future studies are needed to further characterize the impact provided by the physician-pharmacist relationship.

scholarly journals Clinical appraisal of Lodhradi Kashaya on type 2 diabetes mellitus patients

2017 ◽  
Vol 4 (1) ◽  
pp. 58
Author(s):  
Varun K. Singh ◽  
K. R. C. Reddy
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Dosage Form ◽  
Dose Group ◽  
Group A ◽  
Group B

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Lodhradi Kashaya (LKSD) is basically ayurvedic kwath dosage form, described as Madhumehajeet (winner of diabetes mellitus) in ayurvedic classics Basavarajeeyam and the same formulation in Vaidya Chintamani and Charaka Samhita too. The aim of this study was to assess prospectively the drug’s ability in management of type 2 diabetes. </span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">Total 31 patients were taken following the guideline mention in CCRAS protocol for diabetes mellitus research. They are divided into two groups, group A and B, given LKSD 4 g &amp; 2 g TDS respectively for three-month follow up. They are investigated against their blood glucose, HbA1C and liver profile tests. Patients were also investigated for subjective parameters viz polyurea, polyphagia, exhaustion and constipation and their response has also been noted regarding palatability acceptance and ease of administration.</span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Patients has responded positively for formulation. Decrease in FBS and PPBS were found highly significant (P ˂ 0.001) in both groups but more in higher dose (group A). Decrease in HbA1C is also found highly significant in both groups. In LFT, SGOT level were also decreased more in group B in comparison to group A, and it is significant (P = 0.017 and 0.002). SGPT level were also decreased more in group B in comparison to group A, and it is significant in group B (P= 0.085 and 0.002).  </span></p><p class="abstract"><strong>Conclusions:</strong> LKSD is having astringent taste due to tannins and phenols in it. It was found significant not only in controlling blood sugar but also in management of other factors related to diabetes mellitus.</p>

scholarly journals Oral Hypoglycemic Glibenclamide: Can it be a Substitute to Insulin in the Management of Gestational Diabetes Mellitus? A Comparative Study

2012 ◽  
Vol 4 (1) ◽  
pp. 28-31 ◽  
Author(s):  
Partha Mukhopadhyay ◽  
Tara Sankar Bag ◽  
Amit Kyal ◽  
Dipta Prasun Saha ◽  
Noori Khalid
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Birth Weight ◽  
Glycemic Control ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Comparative Study ◽  
Blood Sugar ◽  
Group A ◽  
Group B

ABSTRACT Introduction Gestational diabetes is a common medical disorder in pregnancy. So long, it has been usually treated by insulin. Now it has been found that oral glibenclamide can be used instead of insulin with similar glycemic control and without any adverse maternal and fetal effect. Methods A comparative study between oral glibenclamide and insulin for the management of gestational diabetes mellitus (GDM) was conducted. It was a prospective randomized study and patients attending the antenatal clinic were screened with 75 gm oral glucose between 20 to 28 weeks and GDM was diagnosed based on WHO criteria of 2 hours blood glucose ≥140 mg/dl. Women with gestational diabetes were given medical nutritional therapy (MNT) for 2 weeks. Out of this, 60 women did not achieve the target blood glucose. The goal of treatment was maintenance of mean plasma glucose (MPG) of about 105 mg%. For this the fasting plasma glucose should be around 90 mg/dl and postprandial peaks around 120 mg/dl. Patients were randomly assigned to receive glibenclamide (group A, n = 30) or insulin (group B, n = 30). In group A, glibenclamide was given 2.5 mg orally in morning and doses were increased weekly by 2.5 mg up to a maximum of 20 mg and doses >7.5 mg were given in two divided doses. In group B, insulin 0.7 units per kilogram of body weight at admission was given subcutaneously three times daily and increased weekly as necessary. Self monitoring of blood glucose with glucometer was done. Blood glucose was also measured from the laboratory every week. Glycosylated hemoglobin (HbA1c) was measured before initiation of therapy and repeated in the third trimester before confinement. Terminations of pregnancy in both the groups were done between 37 and 38 weeks. The infant birth weight, blood glucose and serum bilirubin were also recorded in all cases. Results The present study showed that the two groups had similar glycemic status (fasting blood sugar in group A was 103.5 ± 14.62 mg/dl and postprandial blood sugar was 184.1 ± 20.46 mg/dl whereas in group B it was109.3 ± 19.63 mg/dl and 194.3 ± 18.47mg/dl) at the time of entry into the study. The two groups also showed similar levels of glycemic control just before confinement (fasting blood sugar in group A was 88.23 ± 6.55 mg/ dl and postprandial blood sugar was 122.7 ± 10.3 mg/dl whereas in group B it was 88.17 ± mg/dl and 128 ± 12.38 mg/dl) and there was no significant statistical difference in the two groups (p > 0.05). The perinatal outcomes in both the groups were also nearly same. There was no significant difference in birth weight, blood sugar level of neonates and complications between the two groups. There was no case of macrosomia in the two groups and the number of infants large for gestational age (LGA) was four in group A and two in group B. Hypoglycemia in newborn was slightly higher in the group A compared to group B (4 and 3 respectively). Conclusion From our study, it is evident that the use of oral agents is a pragmatic alternative to insulin therapy in cases of gestational diabetes because of similar glycemic control, ease of administration and better patient compliance due to noninvasive treatment. How to cite this article Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral Hypoglycemic Glibenclamide: Can it be a Substitute to Insulin in the Management of Gestational Diabetes Mellitus? A Comparative Study. J South Asian Feder Obst Gynae 2012;4(1):28-31.

scholarly journals Correlation Between Blood Glucose Control And Decrease Of Peripheral Vascularization In Diabetes Mellitus Patient

2018 ◽  
Vol 4 (1) ◽  
pp. 18
Author(s):  
Fitria Endah Janitra ◽  
Dinda Sandika
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Glucose Control ◽  
Diabetes Management ◽  
Blood Glucose Control ◽  
Nursing Intervention ◽  
Tissue Ischemia ◽  
Control Blood Glucose ◽  
Glucose Levels ◽  
Blood Glucose Levels

Introduction: Diabetes mellitus (DM) is a metabolic disorder characterized by elevated blood glucose levels. Chronic complications of DM affect coronary circulation, peripheral vascularization, and blood vessels of the brain. Decrease in peripheral vascularization increases the risk of tissue ischemia and weakens functional status, therefore it is necessary to control blood glucose levels. Islam teaches to its believers to control their diet, where diet is one of the four pillars of diabetes management. Methodology: this is analytic descriptive research with cross sectional methods in 67 respondents taken by consecutive sampling technique. Results: There was a significant correlation within blood glucose control and decreased peripheral vascularization in DM patients (p-value 0.010). Discussion: need further research regarding nursing intervention to control blood glucose.

Microscope-Study on the Relationship between Islet Cell Antibody and Cell Function in Children with Diabetes Mellitus

2021 ◽  
Vol 7 (5) ◽  
pp. 2938-2945
Author(s):  
Xinxia Zhang ◽  
Kunpeng Xu ◽  
Na Zhang
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Blood Glucose ◽  
Glucose Level ◽  
Islet Cell ◽  
Cell Function ◽  
Glucose Levels ◽  
Group A ◽  
Group B ◽  
The Relationship

The purpose of this study was to investigate the relationship between islet cell antibodies and cell function in children with diabetes mellitus. Objective: To investigate the effects of insulin resistance and B-cell failure on blood glucose levels in children with diabetes, so as to provide theoretical basis for rational choice of hypoglycemic drugs and effective control of blood glucose. Methods: 81 children with diabetes mellitus were tested after eating 80g instant noodles for 0, 30, 60,120 min of blood glucose and insulin. All cases were divided into group A (FPG < 8.92mmol /L) and group B (FPG≥ 8.89mmol /L) according to the fasting blood glucose (FFG) level. The contribution of cell function and insulin resistance to the blood glucose level was assessed in both groups. Results: The sensitivity of insulin and true insulin in group B was 65.5% and 64% of that in group A. After adjusting the effect of insulin resistance, the cell function in group B was only 1/5-1/7 of that in group A. Insulin swabs and cell function, measured by insulin, contributed half to glucose levels in group A, while cell function contributed eight times as much to glucose levels as insulin resistance in group B. Beta cell secretory function, measured with true insulin, explained 43% of the change in blood glucose in group A, 55% of the change in blood glucose in group B, and insulin sensitivity explained 13% of the change in group A, and 5.9% of the change in group B. Conclusion: Insulin resistance and cell failure were more serious in the group with higher fasting glucose level (≥ 8.89mmol /L), and the hyperglycemia was mainly caused by cell failure, suggesting that the combination of insulin sensitizer and insulin secretory agent was beneficial in the initial treatment.

scholarly journals Effectiveness of Family Portal Function on Lilly Connected Care Program (LCCP) in Patients with Type 2 Diabetes: a Retrospective Cohort Study with Propensity Score Matching (Preprint)

2020 ◽  
Author(s):  
Yiyu Zhang ◽  
Chaoyuan Liu ◽  
Shuoming Luo ◽  
Jin Huang ◽  
Yuxin Yang ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Diabetes Management ◽  
Diabetes Education ◽  
Care Program ◽  
The Family ◽  
Group A ◽  
Baseline Characteristics ◽  
Group B ◽  
Education Courses

BACKGROUND Diabetes is a major health concern worldwide. Family member engagement in diabetes self-management education programmes can improve patients’ diabetes management. However, there is limited evidence that the family portal on diabetes management apps is effective in the glycaemic control of patients with diabetes. OBJECTIVE We aimed to evaluate the effectiveness of family support through the family portal function on Lilly Connected Care Program® (LCCP®) platform. METHODS This retrospective cohort study included patients with type 2 diabetes (T2DM) recruited to the LCCP platform from September 1, 2018 to August 31, 2019. Propensity score matching was used to match family (group A) and non-family (group B) portal use groups with similar baseline characteristics. The patients were followed up for 12 weeks. The main objectives were differences in mean fasting blood glucose (FBG), proportion of patients achieving FBG target < 7mmol/L, mean postprandial blood glucose (PBG), proportion of patients achieving PBG target <10mmol/L, proportion of patients achieving both FBG <7mmol/L and PBG <10mmol/L, self-monitoring of blood glucose (SMBG) frequency at week 12 and the number of diabetes education courses patients completed during the 12 weeks. Moreover, logistic regression analysis was used to explore the baseline factors which may be associated with the use of family portal, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. RESULTS A total of 6582 adult patients (aged ≥18 years) with T2DM who were treated with insulin were enrolled in the study. Overall, 6.1% (402/6582) of the patients chose to engage their family members to use the family portal. Two groups of 394 patients were well-matched regarding baseline characteristics. After matching, mean FBG and PBG at week 12 were significantly lower in group A than group B (FBG, 7.12 ± 1.70 mmol/L vs. 7.42 ± 1.88 mmol/L, P = .02; PBG, 8.56 ± 2.51 mmol/L vs. 9.10 ± 2.69 mmol/L, P = .002). The proportion of patients achieving both FBG <7mmol and PBG <10mmol/L at week 12 (46.8% vs. 39.4%, P=.04), SMBG frequency at week 12 (8.92 ± 6.77 vs 8.02 ± 5.97 times per week, P = .05) and number of diabetes education courses completed in 12 weeks (23.00 [interquartile range (IQR) 9.00-38.00] vs 15.00 [IQR 4.00-36.00], P<.001) were higher in group A than group B. Besides, multivariate logistic regression analysis showed that higher age (OR=0.987, P=.006) and higher baseline FBG (OR=0.914, P=.004) were correlated with less use of family portal function, while increased baseline SMBG frequency (OR=1.022, P<.001) as well as increased education courses (OR=1.026, P<.001) were associated with more of using family portal function. CONCLUSIONS Family support through the LCCP family portal is effective for glycaemic control and self-management behaviour improvement in T2DM patients.

scholarly journals Different Appearance of Chest CT Images of T2DM and NDM Patients with COVID-19 Pneumonia Based on an Artificial Intelligent Quantitative Method

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Shan Lu ◽  
Zhiheng Xing ◽  
Shiyu Zhao ◽  
Xianglu Meng ◽  
Juhong Yang ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Quantitative Method ◽  
Ct Images ◽  
Chest Ct ◽  
Ground Glass ◽  
Patients With Diabetes ◽  
Group A ◽  
Group B

COVID-19 is a kind of pneumonia with new coronavirus infection, and the risk of death in COVID-19 patients with diabetes is four times higher than that in healthy people. It is unclear whether there is a difference in chest CT images between type 2 diabetes mellitus (T2DM) and non-diabetes mellitus (NDM) COVID-19 patients. The aim of this study was to investigate the differences in chest CT images between T2DM and NDM patients with COVID-19 based on a quantitative method of artificial intelligence. A total of 62 patients with COVID-19 pneumonia were retrospectively enrolled and divided into group A (T2DM COVID-19 pneumonia group, n = 15) and group B (NDM COVID-19 pneumonia group, n = 47). The clinical and laboratory examination information of the two groups was collected. Quantitative features (volume of consolidation shadows and ground glass shadows, proportion of consolidation shadow (or ground glass shadow) to lobe volume, total volume, total proportion, and number) of chest spiral CT images were extracted using Dr. Wise @Pneumonia software. The results showed that among the 26 CT image features, the total volume and proportion of bilateral pulmonary consolidation shadow in group A were larger than those in group B ( P = 0.031 and 0.019, respectively); there was no significant difference in the total volume and proportion of bilateral pulmonary ground glass density shadow between the two groups ( P > 0.05 ). In group A, the blood glucose level was correlated with the volume of consolidation shadow and the proportion of consolidation shadow to right middle lobe volume, and higher than those patients in group B. In conclusion, the inflammatory exudation in the lung of COVID-19 patients with diabetes is more serious than that of patients without diabetes based on the quantitative method of artificial intelligence. Moreover, the blood glucose level is positively correlated with pulmonary inflammatory exudation in COVID-19 patients.

scholarly journals A Brief Review on Management of Gestational Diabetes

2021 ◽  
pp. 462-469
Author(s):  
Nikhil Kaushik ◽  
Dhara Vaghani ◽  
Arpita Jaiswal Singam
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Diabetes Management ◽  
Oral Treatment ◽  
First Line ◽  
High Blood Glucose ◽  
Metabolic Conditions ◽  
Set Up

Gestational diabetes mellitus (GDM) is a real pregnancy trap, wherein ladies without as of late dissected diabetes encourage constant high blood glucose during pregnancy. Diabetes in gestation is a condition where highly increase in the blood glucose level at the period of pregnancy and impacts pregnant ladies who haven't been broke down with diabetes. Diabetes mellitus in gestational period is conceivably most broadly perceived serious the pregnant conditions, with long and short stretch outcomes for mothers, hatchlings & babies. The chiefs & remedies which are wanted to gain most ideal control of glycemia, and while ignoring hypoglycaemia & make sure of fetal and maternal prosperity. This incorporates direct changes, food & treatment, and when considered fundamental; For possible opposing outcomes, simultaneously with fetal and maternal perception was made. The response intends to develop choices for gestational diabetes management treatment pharmacologically. Everyone played out a wide composing different review of examinations, conveyed in the latest fifty year , focusing on  treatment for Gestational diabetes mellitus pharmacologically, overseeing security & ampleness, for maternal & fetal unpleasantness results; similarly like disillusionment & accomplishment in developing legitimate control of glucose and metabolic conditions . Medical treatment orally is a secured & convincing treatment system for GDM and in specific conditions may fill in as first-line treatment while supporting changes misfire. Right when oral experts disregard to set up control of glucose then imbuements of insulin are added supposedly. Choosing oral treatment which is the best in unsure, disregarding the way that it seems, by all accounts, to be that metformin is fairly better compared to glyburide, in specific perspectives. Concerning parenteral treatment, all recorded insulins in the specified article need to be considered both ensured & practical so that the treatment of high blood glucose can be treated in pregnancy. Fundamentally, a prevalent security profile, with near feasibility is recorded for most analogs. As GDM normality climbs, there is a prerequisite for powerful noticing and treatment for patients.

Sign in / Sign up

Export Citation Format

Share Document